Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4

Kuo-Hwa Chiang | Jiunn-Min Shieh | Chih-Jie Shen | Ting-Wei Chang | Pei-Ting Wu | Jinn-Yuan Hsu | Jhih-Peng Tsai | Wen-Chang Chang | Ben-Kuen Chen

Abstract

Epidermal growth factor receptor (EGFR) expression and activation are the major causes of metastasis in cancers such as head and neck squamous cell carcinoma (HNSCC). However, the reciprocal effect of EGF-induced COX-2 and angiopoietin-like 4 (ANGPTL4) on HNSCC metastasis remains unclear. In this study, we revealed that the expression of ANGPTL4 is essential for COX-2-derived prostaglandin E₂ (PGE₂)-induced tumor cell metastasis. We showed that EGF-induced ANGPTL4 expression was dramatically inhibited with the depletion and inactivation of COX-2 by knockdown of COX-2 and celecoxib treatment, respectively. Prostaglandin E₂ induced ANGPTL4 expression in a time- and dose-dependent manner in various HNSCC cell lines through the ERK pathway. In addition, the depletion of ANGPTL4 and MMP1 significantly impeded the PGE₂-induced transendothelial invasion ability of HNSCC cells and the binding of tumor cells to endothelial cells. The induction of molecules involved in the regulation of epithelial-mesenchymal transition was also dependent on ANGPTL4 expression in PGE₂-treated cells. The depletion of ANGPTL4 further blocked PGE₂-primed tumor cell metastatic seeding of lungs. These results indicate that the EGF-activated PGE₂/ANGPTL4 axis enhanced HNSCC metastasis. The concurrent expression of COX-2 and ANGPTL4 in HNSCC tumor specimens provides insight into potential therapeutic targets for the treatment of EGFR-associated HNSCC metastasis.

Keywords

ANGPTL4, EGF, HNSCC, metastasis, PGE₂
Head and neck squamous cell carcinoma (HNSCC) includes cancers of the oral cavity, oropharynx, larynx, and hypopharynx and is the sixth most common malignancy worldwide. \(^1\) Despite advances in the treatment of HNSCC, there has been no significant improvement in mortality rate over the past 40 years. \(^2\) Metastasis is the most significant contributor to the mortality of cancer patients. For example, stage IV HNSCC long-term survival is rare and distant metastasis is a predominant predictor of mortality. \(^3\) The pathogenesis of cancer metastasis involves several processes, including the loss of cellular adhesion, intravasation, survival in the circulation, extravasation, and eventual colonization in the distant metastatic organs. \(^4\)

The success of HNSCC cell extravasation is regulated by matricellular proteins such as angiopoietin-like protein 4 (ANGPTL4), which is highly associated with tumor metastasis. \(^5\)-\(^7\) Interestingly, upregulation of ANGPTL4 has been observed in esophageal SCC and oral tongue SCC. \(^8\);\(^9\) The expression of ANGPTL4 is also essential for EGF-induced HNSCC metastasis. \(^10\) Hypoxic condition-dependent induction of ANGPTL4 by prostaglandin E\(_2\) (PGE\(_2\)) promotes colorectal cancer progression. \(^11\) These results indicate that the expression of ANGPTL4 plays a role in the regulation of tumor metastasis.

A variety of biomarkers including CXC chemokine receptor 2 (CXCR2), CXCR4, interleukin (IL)-6, IL-8, MMPs, and cytokeratins have been reported in HNSCC. \(^11\) The most intensive biomarker, epidermal growth factor receptor (EGFR), is overexpressed in up to 90% of HNSCC compared with normal mucosa. \(^12\);\(^13\) The aberrant activation of EGFR can be achieved by overexpression of EGFR and its ligands, EGFR mutation/polymorphism and transactivation by receptor tyrosine kinases. The intensive association between EGFR expression and HNSCC led to the development of Abs directed against EGFR, such as cetuximab, panitumumab, zalutumumab, and nimotuzumab for treating HNSCC. \(^14\);\(^15\) However, these anti-EGFR inhibitors have shown limited efficacy. Chemoradiation with cetuximab in HNSCC has shown adverse events in clinical trials. \(^16\) In addition, EGFR inhibition by erlotinib or gefitinib is overcome by epithelial-mesenchymal transition (EMT). \(^17\) Potential mechanisms for the failure of EGFR inhibitors in the inhibition of downstream molecules such as Ras/Raf/MAPK, PI3K/AKT/mTOR, and signal transducer and activator of transcription 3 could include the activation of EGFR-independent signaling pathways, including hypoxia and G protein-coupled receptors. \(^18\);\(^19\) The signaling molecules work synergistically with EGFR or compensate for the loss of EGFR-activated signaling and are likely to be targets to overcome EGFR inhibitor resistance.

Similar to EGFR, overexpression of COX-2 is commonly found in both premalignant and malignant tissues. \(^20\) An extensive increase in COX-2 has been found in oral leukoplakia and seems to be correlated with high-grade premalignant lesions. \(^21\) In addition, evidence reveals that COX inhibitors, including nonsteroidal antiinflammatory drugs (NSAIDs), reduce the formation of a variety of tumors. \(^22\);\(^23\) It is worth noting that daily aspirin can significantly prevent distant metastasis in different types of cancer. \(^24\) This evidence suggests the possibility that the activation of COX-2 plays a critical role in cancer progression, including HNSCC. \(^25\) However, the cross-talk between EGFR activation and the expression of ANGPTL4 and COX-2 in promoting HNSCC metastasis remains unclear.

In this study, we reveal for the first time that autocrine production of EGF-induced ANGPTL4 in tumor cells is dependent on the activation of COX-2, resulting in HNSCC metastasis. Prostaglandin E\(_2\) directly promotes the expression of ANGPTL4 to enhance tumor-endothelial cell interactions and lung metastasis of HNSCC cells. Inhibition of ANGPTL4 represents a new strategy for the treatment of EGFR- and COX-2 proinflammatory pathway-associated HNSCC metastasis.
GGAGACCTAGATGTATTGG-3'; antisense, 5'-AGTGCTGTATTGGCA
CGAC-3'), vimentin (sense, 5'-CTGCCCAGCCGATCAACACC-3'; anti-
sense, 5'-CACCTGAGCAGGGTTTTGT-3'), N-cadherin (sense, 5'-GT
GCCATTAGCCAAGGAACTCACG-3'; antisense, 5'-GCGTTCTGTTC
CA CTCAGGAGG-3'), and GAPDH (sense, 5'-CCATCACCATCT
TCCAGGAG-3'; antisense, 5'-CCTGCTTCAACACCTTCTTG-3'). The
PCR products were separated by 2% agarose gel electrophoresis
and visualized with ethidium bromide staining. For the quantitative
RT-PCR, cDNA synthesis was carried out using the Titanium One-Step TR-PCR kit (Clontech) containing SYBR Green I. Real-time
fluorescence monitoring and the melting curve analysis were under-
taken with LightCycler according to the manufacturer’s recom-
mendations. The relative transcript amount of the target gene, calculated
using standard curves of serial RNA dilutions, was normalized to that
of GAPDH of the same RNA.

2.4 | Knockdown experiments

The hairpins targeting COX-2 (shCOX-2) and a nontargeting hairpin
(shLacZ) were obtained from the RNAi Core of the Research Center
of Clinical Medicine, National Cheng Kung University Hospital in the
pLKO.1 lentiviral backbone. Cells were selected in 2 μg/mL puromycin for
3 days and then expanded for 1-2 weeks before analysis. Both shCOX-2
#1 and shCOX-2 #2 stable cell lines were selected from the same tar-
get sequence. Hairpin TRC clone IDs and target sequences were as fol-
lows: shLacZ/TRCN0000072223, TGTTCGCATTATCCGAACCAT; and
shCOX-2/TRCN0000045533, GCTGAATTAAACCCCTCTAT.

2.5 | Transfection of cells with siRNA oligonucleotides or plasmid

Transient transfection of cells with 20 nmol/L siRNA oligonucleo-
tides or plasmid was carried out using RNAiMAX or Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions with
slight modifications. The siRNA IDs were as follows: ANGPTL4,
siRNA IDs HSS181878 and HSS181879; MMP1, siRNA IDs
HSS106609 and HSS106610; and negative control siRNAs, siRNA
ID D-001810-10-50 (Dharmacon). For use in transfection, 3.75 μL
RNAiMAX or Lipofectamine 2000 was incubated with siRNA or
plasmid in 1.5 mL Opti-MEM medium (Invitrogen) for 30 minutes
with RNAiMAX or Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions with slight modifications. Following the removal of Opti-MEM medium,
the cells were incubated with precoated capture Ab at room temperature in a
96-well microplate. After washing, 100 μL detection Ab was added
and incubated for another 2 hours at room temperature, and then
100 μL working dilution of streptavidin-HRP was added to each well
and incubated for 20 minutes under protection from light. After
washing, 100 μL substrate solution was added and incubated for
20 minutes under protection from light. After adding 50 μL stop
solution, the plate was gently tapped to ensure thorough mixing
and an SpectraMax i3x Microplate Absorbance Reader (Molecular
Devices) was used to immediately quantify the optical density at
450 nm.

2.7 | Transendothelial invasion assay

The invasion assay was undertaken using Millicell hanging cell culture
inserts (polyethylene terephthalate membranes with 8-μm pores; Millipore). HMEC-1 cells (1 × 10^5 cells per well) were plated
on the upper chamber and allowed to grow to confluence, and then
10% Matrigel was loaded into the chamber. Tumor cells were treated
with 50 ng/mL EGF or PGE_2 in serum-free medium and then stained
with 1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine per-
chlorate (Dil) (Invitrogen) for 30 minutes. The Dil-stained tumor
cells (2 × 10^5) were then loaded into the chamber, which was filled
with serum-free medium, and incubated for 2 days. Cells on the apical
side of each insert were scraped off. Invasion to the basolateral
side of the membrane was visualized using an immunofluorescent
microscope. The number of invading cells was determined in 3
randomly chosen fields under the microscope for 3 independent
experiments.

2.8 | Cell adhesion assay

Briefly, tumor cells were treated with 20 μmol/L PGE_2 for 3 hours,
then labeled for 30 minutes at 37°C with Dil (Invitrogen) and washed
twice with PBS. The medium was removed from the wells, and tumor
cells (1.5 × 10^5 cells/mL) were added to a monolayer of HMEC-1
cells. After incubation for 30 minutes at 37°C, the wells were gently
washed twice with PBS to remove nonadherent cells. The cells were
photographed and numbers were quantified under a fluorescence
microscope.

2.9 | Tumor metastasis assay in an animal model

Tumor metastasis was determined by tail vein i.v. injection of cancer
cells into 4- to 6-week-old male SCID mice. Briefly, each animal was
injected with 1 × 10^6 cells mixed with PBS, and all mice were killed up
to 2 months after injection. All mice were obtained from the National
Cheng Kung University Laboratory Animal Center (Tainan, Taiwan)
and the National Laboratory Animal Center (Tainan, Taiwan). All
animal experiments in this study were approved by the Laboratory

Animal Committee of National Cheng Kung University. The H&E staining was undertaken by the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital.

3 | RESULTS

3.1 | Expression of ANGPTL4 is dependent on induction of COX-2 in EGF-treated HNSCC cells

Our previous studies revealed that EGF induces the expression of COX-2 or ANGPTL4, resulting in the promotion of tumor metastasis.\(^5\)\(^,\)\(^30\) However, the reciprocal regulation of ANGPTL4 and COX-2 in HNSCC metastasis remains poorly understood. To elucidate the relationship between COX-2 and ANGPTL4 induction in HNSCC, the sequential effect of EGF-induced COX-2 on ANGPTL4 expression was examined in EGF-treated cells. As shown in Figure 1A,B, EGF induced the gene expression of COX-2 and ANGPTL4 in a time-dependent manner. It is worth noting that the induction of COX-2 was earlier than that of ANGPTL4. In addition, the EGF-induced protein expression of ANGPTL4 and COX-2 was further confirmed using ELISA and western blotting, respectively (Figure 1C,D). To further assess the association of EGFR signaling and the expression of ANGPTL4 and COX-2 in HNSCC patients, gene expression signatures in clinical samples were analyzed by The Cancer Genome Atlas data mining.\(^31\) Intriguingly, concurrent expression of EGFR, COX-2, and ANGPTL4 was observed (Figure S1). These results reveal that the induction of COX-2 was followed by ANGPTL4 expression in EGF-treated cells, suggesting the possibility that the expression of ANGPTL4 might be dependent on the expression of COX-2. To assess whether COX-2 activity was essential for EGF-induced ANGPTL4 expression, the selective COX-2 inhibitor celecoxib was used to suppress the activation of COX-2. Indeed, celecoxib significantly inhibited EGF-induced ANGPTL4 mRNA expression and protein secretion in a dose-dependent manner (Figures 2A,B and S2A). The essential role of COX-2 in the regulation of ANGPTL4 expression was also further confirmed by the inhibition of EGF-induced ANGPTL4 that was observed during the depletion of COX-2 (Figure 2C,D); however, EGF-induced COX-2 expression was not changed in ANGPTL4-depleted cells (Figure 2D). These results suggested that the activation and expression of COX-2 are essential for the expression and autocrine secretion of ANGPTL4 in EGF-treated cells.

3.2 | Prostaglandin E\(_2\)-induced ANGPTL4 expression occurs through ERK and peroxisome proliferator activated receptor signaling pathways

To further verify whether the activation of the COX-2 signaling pathway is essential for ANGPTL4 induction, the effect of the COX-2 metabolite PGE\(_2\) on ANGPTL4 expression in HNSCC cell lines was investigated. Quantitative real-time PCR revealed that PGE\(_2\) dramatically induced ANGPTL4 expression in various HNSCC cell lines (Figure 3A). The induction of ANGPTL4 expression by PGE\(_2\) was in a time- and dose-dependent manner (Figures 3B,C and S2B,C). Prostaglandin E\(_2\) showed a weaker induction of ANGPTL4 expression than treatment with EGF (Figure 3D); however, the dysfunction of COX-2 induced by either siCOX-2 or celecoxib led to a reduction of EGF-induced ANGPTL4 that was also reversed by cotreatment with PGE\(_2\) (Figures 3D,E and S2D). These results reveal that the expression of ANGPTL4 in EGF-treated cells.
and activation of COX-2 play an important role in the regulation of ANGPTL4 expression. Furthermore, we confirmed that the ERK activation was also required for PGE$_2$- and EGF-induced ANGPTL4 expression by using the MEK/ERK inhibitor U0126 (Figure 4A,B). The peroxisome proliferator activated receptor (PPAR) binding sequence required for PGE$_2$-induced ANGPTL4 promoter activity was found in a promoter reporter assay (Figure 4C). These results reinforce the essential roles of the ERK and PPAR signaling pathways in the regulation of PGE$_2$-induced ANGPTL4 expression, as well as our previous studies in oleic acid- and EGF-induced ANGPTL4 expression. 5,6

3.3 | Prostaglandin E$_2$-induced ANGPTL4 enhances HNSCC cell metastasis

Overexpression of ANGPTL4 has been identified in various cancers. 32 To test whether ANGPTL4 expression is required for PGE$_2$- and EGF-induced tumor cell invasion, ANGPTL4 siRNA was used in transendothelial invasion assays. As shown in Figure 5A, the depletion of ANGPTL4 inhibited EGF- and PGE$_2$-induced tumor cell transendothelial invasion. In addition, COX-2 siRNA also inhibited EGF-triggered tumor cell transendothelial invasion (Figure 5A). Our previous studies showed that the expression of MMP1 is essential for EGF-induced HNSCC metastasis. 5 Next, we further identified whether MMP1 was required for PGE$_2$-induced cancer cell invasion. As shown in Figure 5A, siMMP1 significantly inhibited PGE$_2$-induced tumor cell invasion. The infiltration of tumor cells into distant locations initially relies on the attachment to endothelial cells. Therefore, we further investigated the effect of EGF- and PGE$_2$-induced ANGPTL4 expression on the interaction between tumor and endothelial cells. As shown in Figure 5B, the EGF- and PGE$_2$-induced tumor-endothelial cell interaction was significantly inhibited in the ANGPTL4-knockdown cells. The depletion of COX-2 also blocked EGF-enhanced tumor-endothelial cell interaction (Figure 5B). These results indicated that PGE$_2$-induced autocrine production of ANGPTL4 stimulated the binding of tumor cells to endothelial cells. The EGF/PGE$_2$/ANGPTL4/MMP1 axis was required for HNSCC invasion.

3.4 | Angiopoietin-like 4 is essential for EMT marker expression and PGE$_2$-primed cancer metastasis

Based on the EGF/PGE$_2$/ANGPTL4/MMP1 axis being essential for PGE$_2$-induced cancer cell invasion, we further studied whether the expression of EMT markers is involved in ANGPTL4-regulated cell
metastasis. As shown in Figure 6, the expression levels of fibronectin, Slug, Snail, Twist, vimentin, and N-cadherin were increased in PGE$_2$-treated cells. In addition, the induction of EMT markers was significantly inhibited in ANGPTL4-depleted cells. In contrast, the induction and inhibition of Snail, Twist, and fibronectin, and E-cadherin by EGF, respectively, were reversed in ANGPTL4-depleted cells (Figure S3). Our previous studies have shown that MMP expression is regulated by ANGPTL4 levels and is associated with cancer metastasis. To clarify whether ANGPTL4 was essential for PGE$_2$-induced MMP expression, the effects of ANGPTL4 depletion on MMP gene expression were examined. Quantitative real-time PCR showed that PGE$_2$-induced expression of MMPs was inhibited in ANGPTL4-depleted cells (Figures 6 and S4). In addition, ANGPTL4 siRNA attenuated EGF-induced expressions of MMP1 and MMP9 (Figure S3), consistent with our previous studies. Because PGE$_2$-induced ANGPTL4 expression promoted expression of EMT markers and MMPs, resulting in tumor cell invasion in vitro studies, we further examined whether ANGPTL4 was essential for PGE$_2$-enhanced metastasis in vivo. Parental and siANGPTL4 cells were pretreated with PGE$_2$ for 3 hours and then injected into the tail veins of mice for 60 days. Hematoxylin and eosin staining showed that the lungs of mice receiving the PGE$_2$-pretreated parental tumor cells contained more and larger micrometastatic colonies than those receiving the PGE$_2$-pretreated siANGPTL4 cells (Figure 7). These results suggest that the induction of ANGPTL4 is essential for PGE$_2$-primed HNSCC metastasis as well as the requirement of ANGPTL4 for EGF-primed tumor metastasis.

**DISCUSSION**

Head and neck squamous cell carcinoma progression is associated with EGFR and/or the proinflammatory pathway, which are targeted by using inhibitors of EGFR and COX-2, such as cetuximab and celecoxib, respectively. Unfortunately, the combination of cetuximab and celecoxib is likely limited in cancer therapy due to anticancer drug resistance and ultimately lack of effect on metastatic tumors. The understanding of cross-talk between EGFR- and COX-2-associated HNSCC metastasis can provide better approaches to treat tumors. In this study, for the first time, we provide evidence that the activation of EGFR signaling promotes the upregulation of COX-2, followed by the induction of ANGPTL4, resulting in the increase of HNSCC metastasis.
However, the production of PGE$_2$ either from EGF-stimulated tumors or surrounding cells, such as tumor-associated macrophages and fibroblasts, has been found to contribute to tumor cell metastasis.$^{30}$ Intriguingly, we found that ANGPTL4 was essential for fibronectin expression and HNSCC metastasis in PGE$_2$-treated cells. These results were consistent with our previous study that showed the expression of ANGPTL4 and fibronectin is also required for EGF- and PGE$_2$-primed HNSCC metastasis, respectively.$^{5,30}$ The studies reveal that the expression of ANGPTL4 and fibronectin is also required for EGF- and PGE$_2$-primed HNSCC metastasis, respectively.$^{5,30}$

The modest effect of the COX-2 inhibitor celecoxib against advanced cancers has been determined from a metaanalysis of clinical trials and there is no significant effect on the 1-year survival rate.$^{36}$ Although COX-2 inhibition is not sufficient to suppress tumor progression, the risk of developing certain cancers, including HNSCC and breast, prostate, and pancreatic cancers, is dramatically reduced,$^{37-40}$ suggesting that selective COX-2 inhibitors have strong potential for the chemoprevention of cancers. Indeed, our studies revealed that the depletion of ANGPTL4 reduced PGE$_2$-primed HNSCC metastasis, suggesting that the inhibition of the inflammatory response, such as the COX-2 signaling pathway, is a new approach to reduce the risk of tumor recurrence by preventing cancer metastasis. In addition, previous studies indicated that COX-2 is involved in immunity-regulated tumor progression. For example, COX-2 inhibitors also suppress tumor immune evasion by inhibiting M2 macrophages and T regulatory cells.$^{41,42}$ Cyclooxygenase-2 in tumor-associated macrophages (TAMs) promotes breast cancer metastasis through the induction of MMP9 and the promotion of EMT in tumor cells.$^{43}$ In addition, cancer-associated fibroblasts (CAFs) are major sources of COX-2/PGE$_2$ in the tumor microenvironment.$^{44}$ These results suggest that the regulation of EMT by PGE$_2$ produced from TAMs, CAFs, or tumors, could further promote tumor metastasis. Considering sources of PGE$_2$ and their wide effect on inflammation-associated tumors, inhibition of the inflammatory response by using NSAIDs or selective COX-2 inhibitors is necessary for the treatment of cancer. Elevated expression of ANGPTL4 also enhances pulmonary tissue leakiness and intensified inflammation-induced lung damage during influenza infection.$^{45}$ These results further suggest that ANGPTL4 might play a role in the regulation of the immune response. Chronic inflammation is highly associated with the risk of developing cancer.$^{46}$ Therefore, whether PGE$_2$-induced ANGPTL4 regulates chronic inflammation-associated tumor progression and immunotherapeutic effects should be further investigated.

In this study, it is worth noting that PGE$_2$-induced EMT markers, including Snail, Slug, Twist, and fibronectin, and MMPs were reduced with the depletion of ANGPTL4 in HNSCC. These results were consistent with the finding that ANGPTL4-regulated EMT participated...
(A) (i) Transendothelial invasion

| Treatment | EGF | siANGPTL4 | siCOX-2 |
|-----------|-----|-----------|---------|
|           | +   | +         | +       |
| EGF       | -   |           | -       |
| siANGPTL4 | SC  | SC        | +       |
| siCOX-2   | -   |           | -       |
| siMMP1    | -   | -         | +       |

(ii) Transendothelial invasion

| Treatment | PGE$_2$ | siANGPTL4 | siMMP1 |
|-----------|---------|-----------|--------|
|           | +       | +         | -      |
| PGE$_2$   | -       |           | -      |
| siANGPTL4 | SC      | SC        | +      |
| siMMP1    | -       |           | +      |

(B) (i) Attachment

| Treatment | EGF | siANGPTL4 | siCOX-2 |
|-----------|-----|-----------|---------|
|           | +   | +         | +       |
| EGF       | -   |           | -       |
| siANGPTL4 | SC  | SC        | +       |
| siCOX-2   | -   |           | -       |
| siMMP1    | -   | -         | +       |

(ii) Attachment

| Treatment | PGE$_2$ | siANGPTL4 |
|-----------|---------|-----------|
|           | +       | -         |
| PGE$_2$   | -       |           |
| siANGPTL4 | -       | -         |
in various tumor metastases. In addition to the regulation of EMT, ANGPTL4 enhances vascular permeability through the integrin pathway to promote tumor metastasis. Our study further provides evidence to suggest that ANGPTL4 also confers metastasis to tumor cells through the enhancement of PGE2-regulated interactions between tumor cells and endothelial cells. These results reveal that the PGE2/ANGPTL4 axis regulates tumor cell migration and invasion through the promotion of tumor-endothelial cell interactions. In addition, previous reports indicated that COX-2 enhances β1 integrin expression to promote non-small-cell lung cancer cell invasion. In our previous studies, we have shown that EGF-induced ANGPTL4 activates the integrin pathway to promote HNSCC metastasis. Together with previous reports and results from this study showing that PGE2-induced ANGPTL4 promotes HNSCC metastasis, we propose that PGE2/ANGPTL4 might regulate tumor cell metastasis through the integrin pathway.

In general, EGF activates the EGFR signaling pathway to induce COX-2 expression and promotes tumor metastasis. In addition to EGF, we provided evidence revealing that the COX-2 metabolite PGE2 triggered tumor metastasis through the induction of ANGPTL4. However, the effect of PGE2 on tumor metastasis might be mediated through the activation of EGFR signaling due to the reciprocal effect of ANGPTL4 on COX-2 expression.
between EGFR signaling and COX-2, which has been found to regulate tumor metastasis. For example, PGE\textsubscript{2} triggers transactivation and phosphorylation of EGFR to promote colorectal cancer cell migration and invasion.\textsuperscript{49} In addition, both EGFR and COX-2 inhibitors, such as erlotinib and celecoxib, respectively, have been used as single agents for chemoprevention in HNSCC.\textsuperscript{50,51} Preclinical and clinical studies have revealed that targeting the EGFR and COX-2 pathways can synergistically inhibit HNSCC growth.\textsuperscript{52-54} Our study also found a strong correlation between the expression of EGFR, COX-2, and ANGPTL4 in HNSCC tumor specimens. Therefore, it is interesting to further investigate whether EGFR inhibitors initiate a direct effect on proinflammatory cytokines in PGE\textsubscript{2}-regulated HNSCC metastasis. In summary, we conclude that targeting ANGPTL4 provides new insight into the treatment of growth factor/inflammation-associated HNSCC metastasis.

ACKNOWLEDGMENTS
This work was supported by the Ministry of Science and Technology of Taiwan (grants NSC 102-2628-B-006-011-MY3, MOST 105-2320-B-006-022-MY3, and 105-2320-B-038-064-MY3).

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

ORCID
Ben-Kuen Chen
https://orcid.org/0000-0002-4720-4364

REFERENCES
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol. 2009;1:6.
3. Hauswald H, Simon C, Hecht S, Debus J, Lindel K. Long-term outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol. 2011;6:70.
4. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-458.
5. Liao Y-H, Chiang K-H, Shieh J-M, et al. Epidermal growth factor-induced ANGPTL4 enhances anoikis resistance and tumour metastasis in head and neck squamous cell carcinoma. Oncogene. 2017;36:2228-2242.
6. Shen CJ, Chan SH, Lee CT, Huang WC, Tsai JP, Chen BK. Oleic acid-induced ANGPTL4 enhances head and neck squamous cell carcinoma anoikis resistance and metastasis via up-regulation of fibronectin. Cancer Lett. 2017;386:110-122.
7. Huang R-L, Teo Z, Chong HC, et al. ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. Blood. 2011;118:3990-4002.
8. Shibata K, Nakayama T, Hirakawa H, Hidaka S, Nagayasu T. Clinicopathological significance of angiopoietin-like protein 4 expression in oesophageal squamous cell carcinoma. J Clin Pathol. 2010;63:1054-1058.
9. Wang Z, Han B, Zhang Z, Pan J, Xia H. Expression of angiopoietin-like 4 and tenascin C but not cathepsin C mRNA predicts prognosis of oral tongue squamous cell carcinoma. Biomarkers. 2010;15:39-46.
10. Kim SH, Park YY, Kim SW, Lee JS, Wang D, DuBois RN. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res. 2011;71:7010-7020.
11. Dahiyi K, Dhanakhar R. Updated overview of current biomarkers in head and neck carcinoma. World J Methodol. 2016;6:77-86.
12. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666-2672.
13. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-3584.
14. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
15. Mesia R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a
32. Tan MJ, Teo Z, Sng MK, Zhu P, Tan NS. Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer Res. 2012;10:677-688.

33. Akishima-Fukasawa Y, Ishikawa Y, Akasaka Y, et al. Histopathological predictors of regional lymph node metastasis at the invasive front in early colorectal cancer. Histopathology. 2011;59:470-481.

34. Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2008;6:742-750.

35. Saba NF, Hurwitz SJ, Kono SA, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase IIb and pharmacokinetic study. Cancer Prev Res (Phila). 2014;7:283-291.

36. Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther. 2014;36:1253-1263.

37. Ahmadi N, Goldman R, Seiller-Moiseiwitsch F, Noone AM, Kost I, Davidson BJ. Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugs. Int J Otalaryngol. 2010;2010:424161.

38. Howe LR, Subbarajaih AA, Patel J, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002;62:5405-5407.

39. Dandekar DS, Lopez M, Carey RI, Lekeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer. 2005;115:484-492.

40. Arjona-Sánchez Á, Ruiz-Rabelo J, Perea MD, et al. Effects of capricetabinbe and celecoxib in experimental pancreatic cancer. Pancreatology. 2010;10:641-647.

41. Palmowski MJ, Gileadi U, Salio M, et al. Role of immunoproteasomes in cross-presentation. J Immunol. 2006;177:983-990.

42. Dubey P, Shrivastava R, Tripathi C, et al. Cyclooxygenase-2 inhibition attenuates hypoxic cancer cells induced m2-polarization of macrophages. Cell Mol Biol (Noisy-le-grand). 2014;60:10-15.

43. Gan LU, Qiu Z, Huang J, et al. Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci. 2016;12:1533-1543.

44. Su CW, Zhang Y, Zhu YT. Stromal COX-2 signaling are correlated with colorectal cancer: a review. Crit Rev Oncol Hematol. 2016;107:33-38.

45. Li L, Chong H, Ng S, et al. Angiopoietin-like 4 increases pulmonary tissue leakiness and damage during influenza pneumonia. Cell Rep. 2015;10:654-663.

46. Muthoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011;2:98.

47. Teo Z, Sng MK, Chan JSK, et al. Elevation of adenosyl energy charge by angiopoietin-like-4 enhances epithelial-mesenchymal transition by inducing 14-3-3gamma expression. Oncogene. 2017;36:6408-6419.

48. Pan J, Yang Q, Shao J, et al. Cyclooxygenase-2 induced beta1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway. Sci Rep. 2016;6:33823.

49. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:35451-35457.

50. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-1952.
53. Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. *Clin Cancer Res*. 2005;11:6261-6269.

54. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. *Mol Cancer Ther*. 2005;4:1448-1455.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.